These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Synthetic vaccines: the role of adjuvants in immune targeting. Jiang ZH; Koganty RR Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139 [TBL] [Abstract][Full Text] [Related]
26. Anti-endotoxic activity and structural basis for human MD-2·TLR4 antagonism of tetraacylated lipid A mimetics based on βGlcN(1↔1)αGlcN scaffold. Garate JA; Stöckl J; Fernández-Alonso Mdel C; Artner D; Haegman M; Oostenbrink C; Jiménez-Barbero J; Beyaert R; Heine H; Kosma P; Zamyatina A Innate Immun; 2015 Jul; 21(5):490-503. PubMed ID: 25394365 [TBL] [Abstract][Full Text] [Related]
27. Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa. Muroi M; Tanamoto K J Biol Chem; 2006 Mar; 281(9):5484-91. PubMed ID: 16407172 [TBL] [Abstract][Full Text] [Related]
28. MPL Adjuvant Contains Competitive Antagonists of Human TLR4. Wang YQ; Bazin-Lee H; Evans JT; Casella CR; Mitchell TC Front Immunol; 2020; 11():577823. PubMed ID: 33178204 [TBL] [Abstract][Full Text] [Related]
30. Elucidation of the MD-2/TLR4 interface required for signaling by lipid IVa. Walsh C; Gangloff M; Monie T; Smyth T; Wei B; McKinley TJ; Maskell D; Gay N; Bryant C J Immunol; 2008 Jul; 181(2):1245-54. PubMed ID: 18606678 [TBL] [Abstract][Full Text] [Related]
31. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Ohto U; Fukase K; Miyake K; Shimizu T Proc Natl Acad Sci U S A; 2012 May; 109(19):7421-6. PubMed ID: 22532668 [TBL] [Abstract][Full Text] [Related]
32. Vitamin D: The unexplored immunomodulator. Das BK; Panda AK Int J Rheum Dis; 2016 Apr; 19(4):332-4. PubMed ID: 27122195 [No Abstract] [Full Text] [Related]
33. Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria. Chilton PM; Hadel DM; To TT; Mitchell TC; Darveau RP Infect Immun; 2013 Sep; 81(9):3317-25. PubMed ID: 23798540 [TBL] [Abstract][Full Text] [Related]
37. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Anderson RC; Fox CB; Dutill TS; Shaverdian N; Evers TL; Poshusta GR; Chesko J; Coler RN; Friede M; Reed SG; Vedvick TS Colloids Surf B Biointerfaces; 2010 Jan; 75(1):123-32. PubMed ID: 19748238 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice. Rostamian M; Niknam HM Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929 [TBL] [Abstract][Full Text] [Related]
39. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264 [TBL] [Abstract][Full Text] [Related]
40. A peptide derived from the core β-sheet region of TIRAP decoys TLR4 and reduces inflammatory and autoimmune symptoms in murine models. Achek A; Kwon HK; Patra MC; Shah M; Hong R; Lee WH; Baek WY; Choi YS; Kim GY; Pham TLH; Suh CH; Kim W; Hahm DH; Choi S EBioMedicine; 2020 Feb; 52():102645. PubMed ID: 32014819 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]